All In Biotech

Drug Trial Radar · NCT03667716

COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.

A Phase 1a/1b Study of COM701 as Monotherapy and In Combination With an Anti-PD-1 Antibody in Subjects With Advanced Solid Tumors.

Last checked: Nov 19, 2026Latest source record: Jan 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

121

Actual

Start

Sep 6, 2018

Primary completion

Jan 30, 2024

Study completion Jan 30, 2024

Sponsor

Lead sponsor
Compugen LtdIndustry
Sponsor type
Industry
Collaborators
Bristol-Myers Squibb
First posted
Sep 12, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary clinical activity of COM701 as monotherapy and in combination with nivolumab.

Conditions

  • Advanced Cancer
  • Ovarian Cancer
  • Breast Cancer
  • Lung Cancer
  • Endometrial Cancer
  • Ovarian Neoplasm
  • Triple Negative Breast Cancer
  • Lung Neoplasm
  • Neoplasm Malignant
  • Colo-rectal Cancer

Interventions

  • COM701Drug

    COM701 monotherapy.

  • COM701 with Opdivo (Nivolumab).Drug

    COM701 in combination with Opdivo (Nivolumab).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of subjects with Adverse Events (AEs) as per CTCAE v4.03 and Dose-Limiting Toxicities (DLTs).Time frame: DLT evaluation window in the 1st cycle (21 or 28 days).
  2. Determine the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RDFE) (COM701 monotherapy and in combination with nivolumab).Time frame: Approximately 2 year.

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • University of California Los Angeles (UCLA).

    Los Angeles, California

  • Florida Cancer Specialists

    Sarasota, Florida

  • University of Chicago Medical Center

    Chicago, Illinois

  • Massachusetts General Hospital

    Boston, Massachusetts

  • START Midwest.

    Grand Rapids, Michigan

  • Columbia University

    New York, New York

  • Cleveland Clinic.

    Cleveland, Ohio

  • The University of Tennessee WEST Cancer Center.

    Memphis, Tennessee

  • Sarah Cannon Research Institute.

    Nashville, Tennessee

  • M D Anderson Cancer Center.

    Houston, Texas

  • The START Center for Cancer Care.

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.